Skip to main content
FutureChem Co., Ltd. logo

FutureChem Co., Ltd. — Investor Relations & Filings

Ticker · 220100 ISIN · KR7220100002 KO Manufacturing
Open in API
Filings indexed 312 across all filing types
Latest filing 2020-06-05 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 220100

About FutureChem Co., Ltd.

https://www.futurechem.co.kr/?language=…

FutureChem Co., Ltd. is a company specializing in the development and production of radiopharmaceuticals for diagnostic and therapeutic applications. The company's operations cover the manufacturing of radiopharmaceutical precursors, chemical compounds, synthesis reagents, and automated synthesis modules. Its product pipeline focuses on agents for the diagnosis and treatment of various cancers and neurological disorders, including Parkinson's disease. FutureChem supports the broader radiopharmaceutical field by providing both finished products and the essential chemical building blocks and equipment required for their synthesis. The company actively establishes global partnerships for clinical supply and commercial licensing of its technologies.

Recent filings

Filing Released Lang Actions
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details a capital increase through a rights offering (shareholder allocation followed by general public offering of unsubscribed shares) for FutureChem Co., Ltd. This document is a formal regulatory filing required for public offerings of securities, which falls under the 'Regulatory Filings' category as it is a primary registration document for capital raising.
2020-06-05 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by FutureChem (주)퓨쳐켐. It details a capital increase (rights offering followed by a public offering of unsubscribed shares), including information on issuance terms, underwriting, risk factors, and financial statements. This is a formal regulatory filing related to capital raising activities, which falls under the 'Capital/Financing Update' category.
2020-06-05 Korean
기타경영사항(특허권취득)(자율공시)(전립선암 진단을 위한 18F-표지된 화합물 및 그의 용도)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a prostate cancer diagnostic compound (FC303). It details the patent name, content, and utilization plan. Since this is a specific regulatory announcement regarding company operations and intellectual property that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2020-06-01 Korean
투자판단관련주요경영사항(PSMA 전립선 암 치료제 FC 705의 국내 임상 1상 시험계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (FutureChem) announcing the approval of a Phase 1 clinical trial for a prostate cancer drug. It follows the standard format for 'Major Management Matters' (주요경영사항) filings in Korea, which are used to disclose material events to the public. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2020-05-28 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'FutureChem' (주식회사 퓨쳐켐) covering the period from January 1, 2020, to March 31, 2020. It contains detailed financial information, business overviews, capital changes, and management discussions, which are characteristic of an interim financial report. It is not an announcement of a report, but the report itself. Q1 2020
2020-05-14 Korean
투자판단관련주요경영사항(전립선암 진단 방사성의약품 FC303 공동개발 기술이전 계약 체결)
M&A Activity Classification · 95% confidence The document is a regulatory filing from a Korean company (FutureChem) announcing a significant business event: a technology transfer and joint development agreement for a prostate cancer diagnostic drug. This type of disclosure, which details a specific material contract, partnership, or licensing agreement, is classified as a general regulatory filing (RNS) as it does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions) or capital financing (which implies fundraising).
2020-05-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.